EPO and chronic kidney disease: Roxadustat administration leads to increases in endogenous EPO levels, with peak increases 8–12 h postdose in healthy volunteers and patients with CKD [61,62,63,64,65] With a half-life of 10 h, roxadustat is administered three times weekly [91].